본문 바로가기
KERD
논문KCI 등재

병원획득 Extended-spectrum ß-Lactamase 생성 Escherichia coli 균혈증의 위험인자

Risk Factors of Nosocomial Bacteremia of Extended-spectrum β-Lactamase Producing Escherichia coli

이지성|박윤수|조용균|문송미|고대식
영남대학교 의과대학 (Yeungnam University College of Medicine)|2013.12|Journal of Yeungnam Medical Science|제30권 제2호|pp. 83-89

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Escherichia coliExtended-spectrum β-lactamaseBacteremiaNosocomial
주제분류의학일반

초록

Background: The prevalence of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli is increasing rapidly worldwide. Treatment options for ESBL-producing E. coli are limited, and infections caused by this organism are associated with improper antibiotic use, a long hospital stay, and increased mortality. Thus, the assessment and early recognition of the risk factors of nosocomial infections due to ESBL-producing E. coli are important for the infection control and proper treatment. Methods: A case-control study was performed that included nosocomial episodes of ESBL-producing E. coli bacteremia at a tertiary care hospital from January 2004 to December 2007. For each case patient, three controls were randomly selected and data on predisposing factors were collected. Results: Fifty-five cases of nosocomial ESBL-producing E. coli bacteremia were studied. Carbapenem usage (OR: 11.3, 95% CI: 1.1-115.9, p=0.041), quinolone usage (OR: 4.5, 95% CI: 1.1-18.8, p=0.042), biliary obstructive disease (OR: 11.8, 95% CI: 3.0-46.7, p<0.001) and the APACHE II score (OR: 1.3, 95% CI: 1.2- 1.5, p<0.001) were analyzed as independent risk factors of nosocomial ESBL-producing E. coli bacteremia. Conclusion: Our results showed that physicians caring for patients with risk factors of nosocomial bacteremia should consider ESBL-producing E. coli as the causative organisms of the disease.

Abstract

Background: The prevalence of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli is increasing rapidly worldwide. Treatment options for ESBL-producing E. coli are limited, and infections caused by this organism are associated with improper antibiotic use, a long hospital stay, and increased mortality. Thus, the assessment and early recognition of the risk factors of nosocomial infections due to ESBL-producing E. coli are important for the infection control and proper treatment. Methods: A case-control study was performed that included nosocomial episodes of ESBL-producing E. coli bacteremia at a tertiary care hospital from January 2004 to December 2007. For each case patient, three controls were randomly selected and data on predisposing factors were collected. Results: Fifty-five cases of nosocomial ESBL-producing E. coli bacteremia were studied. Carbapenem usage (OR: 11.3, 95% CI: 1.1-115.9, p=0.041), quinolone usage (OR: 4.5, 95% CI: 1.1-18.8, p=0.042), biliary obstructive disease (OR: 11.8, 95% CI: 3.0-46.7, p<0.001) and the APACHE II score (OR: 1.3, 95% CI: 1.2- 1.5, p<0.001) were analyzed as independent risk factors of nosocomial ESBL-producing E. coli bacteremia. Conclusion: Our results showed that physicians caring for patients with risk factors of nosocomial bacteremia should consider ESBL-producing E. coli as the causative organisms of the disease.

참고문헌 (42)

  1. Bradford PA, "Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat", Clin Microbiol Rev, 14, pp.933~951 (2001)
  2. Peterson LR, "Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae:the role of piperacillin-tazobactam", Clin Microbiol Infect, 14(Suppl 1), pp.181~184 (2008)
  3. Paterson DL, "Extended-spectrum beta-lactamases:a clinical update", Clin Microbiol Rev, 18, pp.657~686 (2005)
  4. Brun-Buisson C, "Transferable enzymatic resistance to thirdgeneration cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae", Lancet, 2(8554), pp.302~306 (1987)
  5. Sirot J, "Klebsiella pneumonia and other Enterobacteriaceae producing novel plasmid-mediated beta-lactamases markedly active against third-generation cephalosporins: epidemiologic studies", Rev Infect Dis, 10, pp.850~859 (1988)
  6. Rodríguez-Baño J, "Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producingEscherichia coli as a cause of nosocomial infection or colonization:implications for control", Clin Infect Dis, 42, pp.37~45 (2006)
  7. Naas T, "An SHV-derived extended-spectrum beta-lactamase in Pseudomonas aeruginosa", Antimicrob Agents Chemother, 43, pp.1281~1284 (1999)
  8. Itokazu GS, "Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units:evaluation of a national postmarketing surveillance program", Clin Infect Dis, 23, pp.779~784 (1996)
  9. Paterson DL, "International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections", Ann Intern Med, 140, pp.26~32 (2004)
  10. Peña C, "An outbreak of hospital-acquired Klebsiella pneumoniae bacteraemia, including strains producing extended-spectrum beta-lactamase", J Hosp Infect, 47, pp.53~59 (2001)
  11. Cosgrove SE, "The impact of antimicrobial resistance on health and economic outcomes", Clin Infect Dis, 36, pp.1433~1437 (2003)
  12. Schwaber MJ, "Clinical and economic impact of bacteremia with extended-spectrum-beta-lactamase-producing Enterobacteriaceae", Antimicrob Agents Chemother, 50, pp.1257~1262 (2006)
  13. Ramphal R, "Extended-spectrum beta-lactamases and clinical outcomes: current data", Clin Infect Dis, 42(Suppl 4), pp.S164~S172 (2006)
  14. Ho PL, "Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: a case-control study of risk factors and outcomes", Scand J Infect Dis, 34, pp.567~573 (2002)
  15. Peña C, "Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients", Clin Microbiol Infect, 12, pp.279~284 (2006)
  16. Peña C, "Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients:factors influencing mortality", J Hosp Infect, 68, pp.116~122 (2008)
  17. Rodríguez-Baño J, "Risk-factors for emerging bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli", Clin Microbiol Infect, 14, pp.180~183 (2008)
  18. Lautenbach E, "Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes", Clin Infect Dis, 32, pp.1162~1171 (2001)
  19. Tumbarello M, "Predictors of mortality in patients with bloodstream infections caused by extended-spectrumbeta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment", Antimicrob Agents Chemother, 51, pp.1987~1994 (2007)
  20. Rodríguez-Baño J, "Bacteremia due to extendedspectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge", Clin Infect Dis, 43, pp.1407~1414 (2006)
  21. Hyle EP, "Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: variability by site of infection", Arch Intern Med, 165, pp.1375~1380 (2005)
  22. Huang Y, "Risk factors of nosocomial infection with extended-spectrum beta-lactamase-producing bacteria in a neonatal intensive care unit in China", Infection, 35, pp.339~345 (2007)
  23. Rodríguez-Baño J, "Extended-spectrum beta-lactamases in ambulatory care: a clinical perspective", Clin Microbiol Infect, 14(Suppl 1), pp.104~110 (2008)
  24. Calbo E, "Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended- spectrum beta-lactamases", J Antimicrob Chemother, 57, pp.780~783 (2006)
  25. Garner JS, "CDC definitions for nosocomial infections, 1988", Am J Infect Control, 16, pp.128~140 (1988)
  26. Charlson ME, "A new method of classifying prognostic comorbidity in longitudinal studies: development and validation", J Chronic Dis, 40, pp.373~383 (1987)
  27. Clinical Laboratory Standards Institute, "Performance standards for antimicrobial susceptibility testing: 17th informational supplement M100-S17" (2007), Clinical Laboratory Standards Institute
  28. Tumbarello M, "Bloodstream infections caused by extendedspectrum-beta-lactamase-producing Klebsiella pneumoniae:risk factors, molecular epidemiology, and clinical outcome", Antimicrob Agents Chemother, 50, pp.498~504 (2006)
  29. Kang CI, "Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae", Infect Control Hosp Epidemiol, 25, pp.860~867 (2004)
  30. Superti SV, "Risk factors for and mortality of extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli nosocomial bloodstream infections", Rev Inst Med Trop Sao Paulo, 51, pp.211~216 (2009)
  31. Rodríguez-Baño J, "Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-betalactamase-producing Escherichia coli", J Clin Microbiol, 48, pp.1726~1731 (2010)
  32. Owens RC Jr, "Hospital-based strategies for combating resistance", Clin Infect Dis, 42(Suppl 4), pp.S173~S181 (2006)
  33. Kanafani ZA, "Epidemiology and risk factors for extended-spectrum betalactamase-producing organisms: a case control study at a tertiary care center in Lebanon", Am J Infect Control, 33, pp.326~332 (2005)
  34. Graffunder EM, "Risk factors associated with extended-spectrum beta-lactamaseproducing organisms at a tertiary care hospital", J Antimicrob Chemother, 56, pp.139~145 (2005)
  35. Hernández JR, "Nationwide study of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum beta-lactamases in Spain", Antimicrob Agents Chemother, 49, pp.2122~2125 (2005)
  36. Gundes S, "An outbreak of SHV-5 producing Klebsiella pneumoniae in a neonatal intensive care unit; meropenem failed to avoid fecal colonization", New Microbiol, 28, pp.231~236 (2005)
  37. Lipsitch M, "The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions", Proc Natl Acad Sci USA, 97, pp.1938~1943 (2000)
  38. Harris AD, "Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review", Clin Infect Dis, 32, pp.1055~1061 (2001)
  39. D’Agata EM, "Methodologic issues of case-control studies: a review of established and newly recognized limitations", Infect Control Hosp Epidemiol, 26, pp.338~341 (2005)
  40. Behar PR, "The effect of control group selection in the analysis of risk factors for extended spectrum beta-lactamase-producing Klebsiella pneumoniae infections. a prospective controlled study", J Hosp Infect, 68, pp.123~129 (2008)
  41. Melzer M, "Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL)producing E. coli compared to non-ESBL producing E. coli", J Infect, 55, pp.254~259 (2007)
  42. Kim HJ, "Clinical impact of extended-spectrum ß-lactamase-producing Enterobacteriaceae in patients with biliary tract infection", Dig Dis Sci, 58, pp.841~849 (2013)

관련 논문AI추천

Risk Factors and Molecular Epidemiology of Community-Onset Extended-Spectrum β-Lactamase-Producing Escherichia coli Bacteremia김주원, 김준명, 박윤수, 배일권, 이경원, 정석훈, 조용균, 황승식, Yiel Hea Seo연세대학교의과대학 · Yonsei Medical Journal2014 · 제55권 제2호Risk Factors for Extended-Spectrum-β-Lactamase-Producing Escherichia coli in Community-Onset Bloodstream Infection: Impact on Long-Term Care Hospitals in KoreaBaek Yae Jee, Jeong Seok Hoon, Kim Dokyun, Kim Dong-Sook, Kim Young Ah, Lee Eun Ji, Lee Geun Woo, Park Yoon Soo, Shin Jeong Hwan, Shin Jong Hee, Shin Kyeong Seob, Uh Young대한진단검사의학회 · Annals of Laboratory Medicine2021 · 제41권 제5호광범위 베타 락탑계 항생제 분해효소를 생성하는 폐렴간균에 의한 균혈증이 발생한 환자에서 감염의 위험 인자 및 치료 결과강철인, 김성한, 김의종, 김홍빈, 박상원, 방지환, 오명돈, 최강원, 최영주대한감염학회 · Infection and Chemotherapy2003 · 제35권 제2호병원획득 Klebsiella pneumoniae 균혈증 분석을 통해 본 Ciprofloxacin 내성과 Extended- Spectrum β-Lactamase생성 간의 연관성곽이경, 김남중, 김미영, 김성혜, 김양수, 나성수, 류지소, 송문희, 송태준, 우준희, 전재범, 정진용, 최상호, 추은주대한감염학회 · Infection and Chemotherapy2004 · 제36권 제5호영남대학교 의과대학 부속병원에서 동정된 Klebsiella pneumoniae와 Escherichia coli의 Extended-Spectrum β-Lactamase 생성 빈도김경동, 이채훈, 이태수, 이호찬영남대학교 의과대학 · Journal of Yeungnam Medical Science1999 · 제16권 제2호Molecular Characteristics of Extended Spectrum β-Lactamases in Escherichia coli and Klebsiella pneumoniae and the Prevalence of qnr in Extended Spectrum β-Lactamase Isolates in a Tertiary Care Hospital in Korea김명희, 박경선, 서진태, 이희주연세대학교의과대학 · Yonsei Medical Journal2010 · 제51권 제5호

이 간행물의 다른 논문 (18건)

임상시험심사위원회의 임무와 운영김용진pp. 73-78What Is Integrative Medicine ?정승필pp. 79-82The Utility of Basal Serum Luteinizing Hormone Levels for Screening Central Precocious Puberty in Girls정상건, 이영아, 이혜령, 곽민정, 주정기pp. 90-94대구지역 단일병원에서 입원 환아의 호흡기 바이러스 역학 및 임상 양상: 2010-2012년이윤영, 이은경, 최광해pp. 95-100A Case of von Hippel-Lindau Disease with Aortic Valve Insufficiency이혜정, 이동현, 강상현, 조덕송, 이호진, 박인철pp. 101-104
원문 보기